What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
Given recent retrospective study showing potential lack of benefit with bortezomib-based maintenance therapy (Bumma et al., PMID 37021929).
High-risk as defined by: deletion 17p/monosomy 17, t(14;16), t(4;14), t(14;20), or abnormality in 1q (gain or amplification)
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on
This is tough. You want each particular risk group to correspond to a maintenance treatment that is likely to benefit the patient - not too much nor too little.
The definition of high risk has changed from one single characteristic or one cytogenetic abnormality to a more additive model such as the ...
Join for free or sign in to see the full answer